Evidence map›Paper›PMID 36504254›Full record

Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Non-Lactobacillus-Dominant and Polymicrobial Vaginal Microbiomes Are More Common in Younger South African Women and Predictive of Increased Risk of Human Immunodeficiency Virus Acquisition.

Yiran Wang, Laura Noël-Romas, Michelle Perner, Samantha Knodel, Refilwe Molatlhegi, Sarah Hoger, Kenzie Birse, Christina Farr Zuend, Lyle R McKinnon, Adam D Burgener

Registry-linked trialOpen access · bronzeAbstract readClinical Trial
In one paragraph

Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00441298 (Phase IIb Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir Gel for the Prevention of HIV Infection in Women in South Africa), which is not on this map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00441298 phase2completednot on this map

Phase IIb Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir Gel for the Prevention of HIV Infection in Women in South Africa

TypeinterventionalSponsorCentre for the AIDS Programme of Research in South AfricaRan2007 to 2010Enrolled889ConditionsHIV InfectionsArmsTenofovir gel, Placebo (Universal HEC placebo)
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. The Gut-Vagina Axis.Microorganisms · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Disrupted Cervicovaginal Microbiota: Its Role inInternational journal of molecular sciences · 2025
    Review
  10. Article
  11. Bacterial vaginosis.Nature reviews. Disease primers · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 4 countries.

Yiran WangCenter for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Laura Noël-RomasCenter for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Michelle PernerSexually Transmitted Infectious and Bloodborne Pathogens Section, JC Wilt Infectious Disease Research Center, Public Health Agency of Canada, Winnipeg, Canada.
Samantha KnodelCenter for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Refilwe MolatlhegiDepartment of Medical Microbiology, University of KwaZulu-Natal, Durban, South Africa.
Sarah HogerDepartment of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.
Kenzie BirseCenter for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Christina Farr ZuendCenter for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Lyle R McKinnonDepartment of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.
Adam D BurgenerCenter for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Case Western Reserve University · USUniversity of Manitoba · CACenter for Global Health · USPublic Health Agency of Canada · CAUniversity of KwaZulu-Natal · ZA

Funding

Mucosal mechanisms of altered HIV susceptibility in adolescentsR01AI128782 · NIAID · UNIVERSITY OF WASHINGTON · PI KLATT, NICHOLE ROSE · 2017 to 2020
$2.5M
NIAID NIH HHS R01 AI128782
6 · The paper itself

Abstract

backgroundAdolescent girls and young women aged 15‒24 years in sub-Saharan Africa are at disproportionate risk of human immunodeficiency virus (HIV) infection. Given the known association between vaginal microbial dysbiosis and HIV susceptibility, we performed an age-stratified analysis of the vaginal microbiome in South African women and compared this to their risk of HIV acquisition.

methodsVaginal microbiome data were generated by mass spectrometry-based proteomic analysis of cervicovaginal lavages collected from participants (n = 688) in the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 trial. Participants were grouped by age (18-19 years, n = 93; 20-24 years, n = 326; 25-41 years, n = 269).

resultsFour microbiome types were identified based on predominant taxa, including Lactobacillus crispatus (CST-LC, 12.2%), Lactobacillus iners (CST-LI, 43.6%), Gardnerella vaginalis (CST-GV, 26.6%), or polymicrobial (CST-PM, 15.1%). Women aged 18-19 and 20-24 years had increased CST-PM and a non-Lactobacillus-dominant microbiome compared to those 25-41 years (odds ratio [OR], 3.14 [95% confidence interval {CI}, 1.12-7.87], P = .017; OR, 2.81 [95% CI, 1.07-7.09], P = .038, respectively; and OR, 1.65 [95% CI, 1.02-2.65], P = .028; OR, 1.40 [95% CI, 1.01-1.95], P = .030, respectively). The HIV incidence rate of women with CST-PM microbiome was 7.19-fold higher compared to women with CST-LC (hazard ratio [HR], 7.19 [95% CI, 2.11-24.5], P = .00162), which was also consistent in women aged 20-24 years (HR, 4.90 [95% CI, 1.10-21.9], P = .0375).

conclusionsYounger women were more likely to have a higher-risk polymicrobial microbiome suggesting that vaginal microbiota are contributing to increased HIV-1 susceptibility in this group. CLINICAL TRIALS REGISTRATION: NCT00441298.

Indexed as

HIV-1HIV InfectionsMicrobiotaAdolescentFemaleHumansProteomicsRNA, Ribosomal, 16SSouth AfricaVaginaRNA, Ribosomal, 16SHIV transmissionvaginal microbiomeyoung women

Identifiers

PMID36504254
PMCPMC10110272
OpenAlexW4311202297

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.